Anzeige
Mehr »
Freitag, 08.08.2025 - Börsentäglich über 12.000 News
Das Kupferangebot bricht ein - und dieser neue Fund kommt genau zur richtigen Zeit
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QQJB | ISIN: US52886N4060 | Ticker-Symbol:
NASDAQ
08.08.25 | 17:40
0,859 US-Dollar
+3,49 % +0,029
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
LEXARIA BIOSCIENCE CORP Chart 1 Jahr
5-Tage-Chart
LEXARIA BIOSCIENCE CORP 5-Tage-Chart

Aktuelle News zur LEXARIA BIOSCIENCE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiLexaria Bioscience Corp.: GLP-1 "Arms Race" Broadens to Include Dozens of Companies203Lexaria highlights DehydraTECH's adverse events improvement opportunity KELOWNA, BC / ACCESS Newswire / August 6, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria")...
► Artikel lesen
29.07.H.C. Wainwright senkt Kursziel für Lexaria Bioscience wegen Aktienverwässerung1
29.07.H.C. Wainwright lowers Lexaria Bioscience stock price target on share dilution2
28.07.Lexaria Bioscience Corp.: Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study633DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus®DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus®DehydraTECH-GLP-1...
► Artikel lesen
23.07.Lexaria's DehydraTECH reduces side effects in GLP-1 drugs4
23.07.Lexaria Bioscience Corp.: Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry238The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted side effectsDehydraTECH reduces side effects and could support patient retention...
► Artikel lesen
LEXARIA BIOSCIENCE Aktie jetzt für 0€ handeln
14.07.Lexaria Bioscience Corp. - 10-Q, Quarterly Report1
01.07.Kursziel für Lexaria Bioscience von H.C. Wainwright auf 5 US-Dollar gesenkt2
01.07.Lexaria Bioscience stock price target lowered to $5 at H.C. Wainwright1
23.06.Lexaria Bioscience expands patent portfolio to 50 with new additions5
23.06.Lexaria Bioscience Corp.: Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide202New patents received for the treatment of epilepsy and for the sublingual delivery of nicotine KELOWNA, BC / ACCESS Newswire / June 23, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the...
► Artikel lesen
12.06.Lexaria Bioscience Corp. - 8-K, Current Report2
11.06.Lexaria Bioscience Corp.: Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule258Oral DehydraTECH-liraglutide showed a pronounced reduction in adverse events ("AEs") as compared to injected liraglutide (Saxenda(R)) Lexaria has now demonstrated, in distinct human clinical studies...
► Artikel lesen
05.06.Lexaria Bioscience Corp.: Lexaria Attending BIO International Convention254Biotechnology Sector's Premier Strategic Partnering Event KELOWNA, BC / ACCESS Newswire / June 5, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator...
► Artikel lesen
12.05.Lexaria advances drug delivery tech with PharmaCO2
12.05.Lexaria Bioscience Corp.: Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company871KELOWNA, BC / ACCESS Newswire / May 12, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update on corporate...
► Artikel lesen
28.04.Lexaria Bioscience Corp. - 8-K, Current Report2
28.04.Lexaria Bioscience Corp.: Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock332KELOWNA, BC / ACCESS Newswire / April 28, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the...
► Artikel lesen
25.04.Lexaria Bioscience announces $2M registered direct offering; shares slip 19%4
25.04.Pre-market Movers: Odyssey Marine Exploration, SES AI, VYNE Therapeutics, The OLB Group, Lexaria Bioscience858OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.30 A.M. ET).In the Green Odyssey Marine Exploration, Inc. (OMEX) is up over...
► Artikel lesen
Weiter >>
71 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1